Regentis生物材料的无溶剂GelrinC液凝,产值高400%,没有有毒溶剂,接近美国批准治疗膝部软骨损伤。 Regentis Biomaterials' solvent-free GelrinC hydrogel, with 400% higher yield and no toxic solvents, is nearing U.S. approval for treating knee cartilage injuries.

Regentis生物材料开发了一种无溶剂制造工艺并将其专利授予GelrinC水凝,将产量提高400%,并消除有毒溶剂。 Regentis Biomaterials has developed and patented a solvent-free manufacturing process for its GelrinC hydrogel, boosting production yield by 400% and eliminating toxic solvents. 该程序在印度、中国和以色列获得专利,美国的申请尚待处理。 The process is patented in India, China, and Israel, with a U.S. application pending. GelrinC在欧洲已经是CE标记,预定在2026年在那里进行商业发射,林业发展局正在对一项关键试验进行审查,其目标患者有一半以上已经登记在案。 GelrinC, already CE Marked in Europe, is set for a 2026 commercial launch there and is under FDA review in a pivotal trial with over half of its target patients enrolled. 它为单一10分钟的程序设计,目的是在美国市场长达5年多的时间里提供持久的疼痛缓解和改善功能,美国市场每年有47万个膝盖软骨损伤病例,目前没有现成的治疗。 Designed for a single 10-minute procedure, it aims to provide lasting pain relief and improved function for over five years in the U.S. market’s 470,000 annual knee cartilage injury cases, where no off-the-shelf treatment currently exists.